News and Trends 8 Aug 2025 Top biotech deals in July 2025 …million) in milestone payments in exchange for jointly developing BioVersys’s BV500 program, specifically the antibiotic ansamycin. To treat metabolic diseases, Pennsylvania-based Madrigal Pharmaceuticals and Chinese company CSPC Pharmaceutical Group Limited… August 8, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Oct 2025 Eight AI deals in 2025: Discover where industry leaders are betting big …treat diseases across chronic indications, including a preclinical small molecule oral therapy for immunological diseases. The deal also stated that the research would be carried out by CSPC in Shijiazhuang… October 28, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 22 Jan 2019 No Guts, No Glory: How Microbiome Research is Changing Medicine …metabolic indications,” Isabelle de Cremoux, CEO of Seventure, told me. “Then we saw innovations applied to the field of autoimmune and immune diseases. Then skincare popped up and more recently… January 22, 2019 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Opinion 26 Apr 2023 Can mRNA vaccines tackle multiple diseases? …vaccines to protect people of all ages from diseases and deliver immunization. Although vaccination is one of the most effective public health interventions to prevent, control and even eradicate diseases,… April 26, 2023 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 2 May 2024 Eight monoclonal antibody biotechs making strides in the clinic …company Regeneron also has over 25 monoclonal antibodies in various stages of clinical development to address conditions ranging from anemia and metabolic diseases to cancer, inflammatory diseases, and rare diseases…. May 2, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 26 Jul 2024 Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies …strategic choice to focus its pipeline on endocrine and metabolic diseases. “Rare endocrine diseases can be an opportunity for Confo to go into late-stage development and even commercialization, while big… July 26, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 8 Dec 2023 Can worms provide treatments for some diseases? U.S. company Holoclara is looking to tackle diseases through the development of worm-derived therapeutics. Allergic and autoimmune diseases were first described in the early 1900s, which Holoclara said is the… December 8, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2023 The promise of immunotherapy for autoimmune diseases …on healthy cells and tissues? For the millions of people battling autoimmune diseases, this can severely affect their lives. However, advances in immunotherapy have revolutionized how these autoimmune diseases are… June 27, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jan 2025 A surge in deals: GSK bets on ADC, neuro and fibrotic diseases to bolster drug development …known for its focus on infectious diseases, lung diseases, and cancer, also seems to be willing to spread its wings across new indications. The company has now forged a partnership… January 2, 2025 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Poxel granted orphan drug designation for kidney disease treatment …of lipid metabolism, glucose homeostasis and inflammation. Based on its central metabolic role, targeting AMPK offers the opportunity to pursue a wide range of indications to treat chronic metabolic diseases…. October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Jul 2025 Seven biotechs in Belgium making leaps in the clinic …with many body functions. Belgium-based biotech company MRM Health aims to harness the gut microbiome to develop therapies for inflammatory, CNS, and metabolic diseases. Its clinical candidate MH002 is being… July 22, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 May 2025 Nine promising small molecule drug discovery companies to look out for in 2025 …identify and develop therapies using Light Horse’s platform. Maze Therapeutics Disease areas: Renal and cardiometabolic diseases Lead candidate: MZE829 Recent news: Dosed the first patient in a phase 2 trial… May 16, 2025 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email